Futur Publishes Annual and Sustainability Report for 2024
Today, Futur Pension AB (publ) publishes its Annual and Sustainability Report for 2024. Read it at www.futur.se/financial-information
We are pleased to note that Futur’s customers overall have experienced strong returns in 2024. In particular, customers with exposure to global equities, led by the U.S. market, have seen significant growth of their capital. Thereto, we are proud of high inflows of new savings and pension capital.
In line with last years, Futur has continued to invest heavily in its technology platform to ensure a high level of service and cost efficiency.
“For the coming years, we see great opportunities to continue growing by developing innovative and efficient services for savings and pension together with our partners. In 2025, we will continue our investments in digital self-service solutions to strengthen our position as the obvious choice for savings and pensions. We also look forward to more and deeper collaborations throughout the year,” says Torgny Johansson, CEO of Futur.
Key highlights 2024:
- New digital self-service interface for private customers which has contributed to reducing routine calls to customer service by more than 30%
- Awarded most innovative company and the company with the best product range in Origo’s annual survey among financial advisors in Sweden
- 4 new partners and 23,000 new customers
- 80% Y-on-Y growth in the occupational pension portfolio bond product
- Continued revenue growth (+24% Y-on-Y) and 50% higher net inflows than in 2023
Futur’s positive development continued in 2024, and the profit grew by 33% to 420 million SEK (compared to SEK 316m in 2023). This increase is explained by growing net inflows, strong returns on customers’ capital, and cost efficiency.
Key financial figures 2024 (2023):
- Revenue 998 MKR (806)
- Sales costs 459 MKR (371)
- Admin costs 119 MKR (119)
- Profit 420 MKR (316)
- Proposed dividend 350 MKR (275) corresponding to over 80% of profit
Read more in the annual report at www.futur.se/financial-information
Futur provides digital infrastructure for the savings and pension market. With our modern platform, we efficiently connect products and customers through partners who offer professional advice. Our platform enables partners to offer better savings options cost-effectively, helping more people achieve a richer and more secure future. Futur has more than 50 partners and 300,000 customers, with 235 billion SEK in savings and pension capital. For more information, visit www.futur.se
The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-17 11:00 CET.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317622387/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Trust in Digital Services Declines, Finds Thales18.3.2025 09:00:00 CET | Press release
Thales 2025 Digital Trust Index reveals most industries experienced a decline in consumer trust compared to last year Privacy fears are becoming a major factor in consumer decisions to abandon brands. 82% doing so last year Banking tops the Trust Index for the second year in a row, but levels of trust fall to just 32% among Gen Z customers 33% of consumers voiced frustration with ecommerce, directly caused by bad bots manipulating the customer purchasing process Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands an
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 09:00:00 CET | Press release
Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments i
ATLAS Welcomes Strengthened Commitment to Increased Shareholder Returns from SES Board18.3.2025 08:43:00 CET | Press release
ATLAS supports the decision to modernize BoardATLAS welcomes SES’s strengthened commitment to increased shareholder returns and capital disciplineATLAS will continue to work with management and stakeholders to increase shareholder value ATLAS Infrastructure (“ATLAS”) is a specialist listed infrastructure investor managing funds on behalf of long-term infrastructure clients. ATLAS’s actively managed accounts currently hold in aggregate a greater than 10% voting interest and 12.5% economic interest in SES S.A (“SES” or the “Company”). ATLAS supports the decision from the SES Board of Directors (“the Board”) to further strengthen Company governance through a modernisation of the Board structure and composition. Introducing further capital markets experience into a reduced Board of 9 increases alignment of stakeholder interests. ATLAS looks forward to continuing its engagement with the Board, the Nomination Committee and other Significant Stakeholders to assist with finding the best possib
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 07:00:00 CET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 07:00:00 CET | Press release
Dr. Martin Leon to Chair the New Scientific Advisory Board (SAB) of Protembis which will also include Dr Anita Asgar, Dr Samir Kapadia and Dr Nicolas van Mieghem Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom